Evidence map›Paper›PMID 38841782›Full record

ArticleHaematologica2024

Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments.

Marine Baron, Karim Labreche, Marianne Veyri, Nathalie Désiré, Amira Bouzidi, Fatou Seck-Thiam, Frédéric Charlotte, Alice Rousseau, Véronique Morin, Cécilia Nakid-Cordero and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Marine BaronSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France; Sorbonne Université, Department of Clinical Haematology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris. marine.baron@aphp.fr.
Karim LabrecheSorbonne Université, CinBioS, UMS 37 PASS Production de données en Sciences de la vie et de la Santé, INSERM, 75013 Paris.
Marianne VeyriSorbonne Université, INSERM, Pierre et Louis Institute of Epidemiology and Public Health, F-75013 Paris France, Theravir Team, Department of Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Nathalie DésiréSorbonne Université, CinBioS, UMS 37 PASS Production de données en Sciences de la vie et de la Santé, INSERM, 75013 Paris.
Amira BouzidiSorbonne Université, INSERM, Research Unit on Cardiovascular and Metabolic Disease UMR ICAN, Department of Endocrine Biochemistry and Oncology, AP-HP, Hôpital-Pitié-Salpêtrière, F-75013 Paris.
Fatou Seck-ThiamSorbonne Université, CinBioS, UMS 37 PASS Production de données en Sciences de la vie et de la Santé, INSERM, 75013 Paris.
Frédéric CharlotteSorbonne Université, Department of Anatomy and Pathologic Cytology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Alice RousseauSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Véronique MorinSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Cécilia Nakid-CorderoSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Baptiste AbbarSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Alberto PiccaSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Marie Le CannDepartment of Clinical Haematology, AP-HP, Hôpital Kremlin Bicêtre, F-94270 Le Kremlin.
Noureddine BalegrouneSorbonne Université, Department of Clinical Haematology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Nicolas GauthierSorbonne Université, Department of Clinical Haematology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Ioannis TheodorouDepartment of Immunology, Hôpital Robert Debré, F-75019, Paris.
Mehdi TouatSorbonne Université, INSERM, CNRS, Brain and Spine Institute, ICM, Department of Neurology 2-Mazarin, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Véronique MorelSorbonne Université, Department of Clinical Haematology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Franck BielleSorbonne Université, Department of Neuropathology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013, Paris.
Assia SamriSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Agusti AlentornSorbonne Université, INSERM, CNRS, Brain and Spine Institute, ICM, Department of Neurology 2-Mazarin, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Marc SansonSorbonne Université, INSERM, CNRS, Brain and Spine Institute, ICM, Department of Neurology 2-Mazarin, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Damien Roos-WeilSorbonne Université, Department of Clinical Haematology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Corinne HaiounLymphoid malignancies Unit, AP-HP, Mondor Hospital, F-94000 Créteil.
Elsa PoullotDepartment of Anatomy and Pathologic Cytology, AP-HP, Mondor Hospital, F-94000 Créteil.
Anne Langlois De SeptenvilleSorbonne Université, INSERM, Centre de Recherche des Cordeliers, Department of Biological Hematology, AP-HP, Hôpital Pitié-Salpêtrière, Paris.
Frédéric DaviSorbonne Université, INSERM, Centre de Recherche des Cordeliers, Department of Biological Hematology, AP-HP, Hôpital Pitié-Salpêtrière, Paris.
Amélie GuihotSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Pierre-Yves BoelleSorbonne Université, CinBioS, UMS 37 PASS Production de données en Sciences de la vie et de la Santé, INSERM, 75013 Paris.
Véronique LeblondSorbonne Université, Department of Clinical Haematology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Florence CouletSorbonne Université, INSERM, Saint-Antoine Research Center, Microsatellites Instability and Cancer, CRSA, Department of Medical Genetics, AP-HP, Pitié-Salpêtrière Hospital, F-75013 Paris.
Jean-Philippe SpanoSorbonne Université, INSERM, Pierre et Louis Institute of Epidemiology and Public Health, F-75013 Paris France, Theravir Team, Department of Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Sylvain ChoquetSorbonne Université, Department of Clinical Haematology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.
Brigitte AutranSorbonne Université, INSERM U1135, Center for Immunology and Infectious Diseases (CIMI), Department of Immunology, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-Hodgkin lymphomas (NHL) commonly occur in immunodeficient patients, both those infected by human immunodeficiency virus (HIV) and those who have been transplanted, and are often driven by Epstein-Barr virus (EBV) with cerebral localization, raising the question of tumor immunogenicity, a critical issue for treatment responses. We investigated the immunogenomics of 68 lymphoproliferative disorders from 51 immunodeficient (34 post-transplant, 17 HIV+) and 17 immunocompetent patients. Overall, 72% were large B-cell lymphoma and 25% were primary central nervous system lymphoma, while 40% were EBV+. Tumor whole-exome and RNA sequencing, along with a bioinformatics pipeline allowed analysis of tumor mutational burden, tumor landscape and tumor microenvironment and prediction of tumor neoepitopes. Both tumor mutational burden (2.2 vs. 3.4/Mb, P=0.001) and numbers of neoepitopes (40 vs. 200, P=0.00019) were lower in EBV+ than in EBV- NHL, regardless of the immune status. In contrast both EBV and the immune status influenced the tumor mutational profile, with HNRNPF and STAT3 mutations observed exclusively in EBV+ and immunodeficient NHL, respectively. Peripheral blood T-cell responses against tumor neoepitopes were detected in all EBV- cases but in only half of the EBV+ ones, including responses against IgH-derived MHC-class-II restricted neoepitopes. The tumor microenvironment analysis showed higher CD8 T-cell infiltrates in EBV+ versus EBV- NHL, together with a more tolerogenic profile composed of regulatory T cells, type-M2 macrophages and an increased expression of negative immune-regulators. Our results highlight that the immunogenomics of NHL in patients with immunodeficiency primarily relies on the tumor EBV status, while T-cell recognition of tumor- and IgH-specific neoepitopes is conserved in EBV- patients, offering potential opportunities for future T-cell-based immune therapies.

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanLymphoma, Non-HodgkinMutationTumor MicroenvironmentAdultAgedFemaleHumansImmunocompromised HostImmunogeneticsMaleMiddle AgedYoung Adult

Identifiers

PMID38841782
PMCPMC11532699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.